Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan-Mar;64(1):65-71.
doi: 10.47162/RJME.64.1.08.

Molecular prognostic factors in colorectal cancer: 5-year follow-up

Alina Elena Ciobanu  1 , Daniel Cristian Pîrvu, Cristina Maria Mărginean, Anda Lorena Dijmărescu, Adriana Estefa Muñoz-Groza, Cristian Meşină, Tudor Adrian Bălşeanu, Vlad Dumitru Băleanu, Tiberiu Ştefăniţă Ţenea-Cojan, Daniela Ciobanu
Affiliations

Molecular prognostic factors in colorectal cancer: 5-year follow-up

Alina Elena Ciobanu et al. Rom J Morphol Embryol. 2023 Jan-Mar.

Abstract

Colorectal cancer (CRC) is a frequently diagnosed and lethal disease. The risk of developing CRC is determined by environmental and genetic factors. Surgical treatment is the main curative modality for patients with CRC up to stage III. In recent years, a special place has been given to biological agents used as targeted therapy following the genetic analysis of the tumor: Bevacizumab (Avastin), Cetuximab (Erbitux), Ziv-aflibercept (Zaltrap). We present a study based on 46 colorectal tumor resection specimens from patients operated for CRC in the Surgery Departments of the Emergency County Clinical Hospital of Craiova, Romania. Histopathological examination and immunohistochemistry staining of tissue sections were performed to determine the degree of aggressiveness. Using the Kaplan-Meier test, we calculated the correlation coefficient between survival time and immunohistochemical prognostic factors. The patients were followed for 60 months postoperatively.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interests.

Figures

Figure 1
Figure 1
Tumor invasion in adjacent structures related to the rectal wall: (A) Invasion in the lymphatic vessels; (B) Invasion in the blood vessels; (C) Perineural invasion. Hematoxylin–Eosin (HE) staining: (A–C) ×100.
Figure 2
Figure 2
Microscopic images of lymph nodes with metastases: (A) G1 colorectal adenocarcinoma; (B) Mucinous carcinoma. HE staining: (A and B) ×40.
Figure 3
Figure 3
Microscopic image of well-differentiated adenocarcinoma with moderate (A) or intense (B) reaction to Ki67 proliferation antigen. Immunolabeling with anti-Ki67 antibody: (A and B) ×200.
Figure 4
Figure 4
Distribution of Ki67 immunostaining intensity according to age.
Figure 5
Figure 5
Kaplan–Meier survival curves according to the results of IHC analysis: (A) Ki67; (B) p53; (C) VEGF; (D) HER2/neu. HER2: Human epidermal growth factor receptor 2; IHC: Immunohistochemistry; VEGF: Vascular endothelial growth factor.
Figure 6
Figure 6
Rectal adenocarcinoma with weak (A) and intense (B) reaction to p53 antigen. Immunolabeling with anti-p53 antibody: (A and B) ×200.
Figure 7
Figure 7
VEGF immunohistochemical staining of primary rectal adenocarcinoma: (A) Absent reaction; (B) Intense reaction. Immunolabeling with anti-VEGF antibody: (A and B) ×200.
Figure 8
Figure 8
Correlation of VEGF immunoexpression with the invasion stage in the rectal wall.
Figure 9
Figure 9
Rectal adenocarcinoma samples displaying absent (A, score 0), weak (B, score 1+) and moderate (C, score 2+) HER2/neu membranous immunoreactivity. Immunolabeling with anti-HER2/neu antibody: (A–C) ×200.
See this image and copyright information in PMC

References

    1. Weir HK, Thun MJ, Hankey BF, Ries LAG, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN, Edwards BK. Annual Report to the Nation on the Status of Cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003;95(17):1276–1299. - PubMed
    1. Pătraşcu Ş, Cercelaru L, Graure GM, Firuţ MA, Rotaru I, Cârţu D, Marinescu D, Pătraşcu AM, Radu RI, Mitroi G, Şurlin V. The histopathological features and their prognostic impact in the postoperative follow-up of colorectal cancer patients. Rom J Morphol Embryol. 2022;63(3):555–561. - PMC - PubMed
    1. Feldman M , Friedman LS , Brandt LJ , et al., editors. leisenger and Fordtran’s gastrointestinal and liver disease: pathophysiology, diagnosis, management . 10 . Philadelphia, PA, USA : Saunders/Elsevier ; 2016.
    1. Ilie DS, Mitroi G, Păun I, Ţenea-Cojan TŞ, Neamţu C, Totolici BD, Sapalidis K, Mogoantă SŞ, Murea A. Pathological and immunohistochemical study of colon cancer. Evaluation of markers for colon cancer stem cells. Rom J Morphol Embryol. 2021;62(1):117–124. - PMC - PubMed
    1. Moran EM. Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. J Environ Pathol Toxicol Oncol. 2002;21(2):193–201. - PubMed